Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: Involvements of Bcl-2 and Bax

Neuropharmacology

Volumn 46, Issue 8, 2004, Pages 1130-1140

  Youdim, Moussa B H ^a   Arraf, Zaher ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bax; Bcl 2; DA, dopamine; DOPA, dihdroxyphenylalanine; DOPAC, dihydroxyphenylacetic acid; Dopaminergic neurons; GSK 3beta; HVA, homovanilic acid; Lithium; MAO, monoamine oxidase; MPP+, dihydropridimium ion; MPTP; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; HOMOVANILLIC ACID; LITHIUM; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CORPUS STRIATUM; DIET; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN INDUCTION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; DOPAMINE; LITHIUM; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 1942468747     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.02.005     Document Type: Article

References (56)

1. 3 on the superoxide dismutase and glutathione peroxidase activities of rat brain, liver and erythrocytes. Biochem. Mol. Biol. Int. 34:1994;1085-1090.
2. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B.H., Naoi M. An anti-Parkinson's disease drug,N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326:2002;105-108.
3. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M.B.H., Tsujimoto Y., Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82:2002;913-923.
4. Belmaker R.H., Bersudsky Y., Agam G., Levine J., Kofman O. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Annu. Rev. Med. 47:1996;47-56.
5. Ben-Shachar D., Youdim M.B. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57:1991;2133-2135.
6. Bosetti F., Seemann R., Bell J.M., Zahorchak R., Friedman E., Rapoport S.I., Manickam P. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res. Bull. 57:2002;205-209.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Carrillo M.C., Minami C., Kitani K., Maruyama W., Ohashi K., Yamamoto T., Naoi M., Kanai S., Youdim M.B.H. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67:2000;577-585.
9. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA. 96:1999;8745-8750.
10. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
11. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274:1999;6039-6042.
12. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T., Leeds P. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 4:2002;129-136.
13. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 43:2002;1158-1164.
14. Erakovic V., Zupan G., Varljen J., Laginja J., Simonic A. Lithium plus pilocarpine induced status epilepticus - biochemical changes. Neurosci. Res. 36:2000;157-166.
15. Finberg J.P., Lamensdorf I., Weinstock M., Schwartz M., Youdim M.B.H. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol. 80:1999;495-499.
16. Grime J.K., Vickers T.J. Determination of lethium in microliter samples of blood serum using flame atomic emission spectrometry with a tantalum filament vaporizer. Anal. Chem. 47:1975;432-435.
17. Grunblatt E., Mandel S., Maor G., Youdim M.B.H. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78:2001;1-12.
18. Grunblatt E., Mandel S., Maor G., Youdim M.B.H. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J. Neurochem. 77:2001;146-156.
19. Hashimoto R., Takei N., Shimazu K., Christ L., Lu B., Chuang D.M. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology. 43:2002;1173-1179.
20. Hashimoto R., Fujimaki K., Jeong M.R., Christ L., Chuang D.M. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett. 538:2003;145-148.
21. Heikkila R.E., Duvoisin R.C., Finberg J.P., Youdim M.B.H. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116:1985;313-317.
22. Hennion J.P., el-Masri M.A., Huff M.O., el-Mailakh R.S. Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord. 4:2002;201-206.
23. Kato T., Horiuchi S., Togari A., Nagatsu T. A sensitive and inexpensive high-performance liquid chromatographic assay for tyrosine hydroxylase. Experientia. 37:1981;809-811.
24. Keller R., Oke A., Mefford I., Adams R. Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci. 19:1976;995-1003.
25. King T.D., Bijur G.N., Jope R.S. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919:2001;106-114.
26. Mandel S., Grunblatt E., Maor G., Youdim M.B.H. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 27:2002;1231-1243.
27. Mandel S., Grunblatt E., Riederer P., Levites Y., Youdim M.B.H. Neuroprotective strategies in Parkinson's disease: An update on progress. CNS Drugs. 17:2003;729-762.
28. Manji H.K., Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry. 7:2002;S46-S56.
29. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychol. 46:1999;929-940.
30. Manji H.K., Moore G.J., Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br. J. Psychiatry Suppl. 41:2001;s107-s119.
31. Maruyama W., Akao Y., Youdim M.B.H., Boulton A.A., Davis B.A., Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78:2001;727-735.
32. Maruyama W., Takahashi T., Youdim M.B.H., Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109:2002;467-481.
33. Maruyama W., Akao Y., Carrillo M., Kitani K., Youdium M., Naoi M. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24:2002;675-682.
34. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport. 9:1998;2081-2084.
35. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl Acad. Sci. USA. 95:1998;2642-2647.
36. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hochman A., Gorodin S., Melamed E., Bernard R., Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci. USA. 95:1998;5789-5794.
37. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA. 93:1996;4565-4571.
38. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16:2000;135-142.
39. Shaldubina A., Agam G., Belmaker R.H. The mechanism of lithium action: state of the art, ten years later. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;855-866.
40. Shimoke K., Chiba H. Nerve growth factor prevents 1-methyl-4-phenyl-1,2, 3,6- tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J. Neurosci. Res. 63:2001;402-409.
41. Speiser Z., Mayk A., Eliash S., Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106:1999;593-606.
42. Tatton W.G., Wadia J.S., Ju W.Y., Chalmers-Redman R.M., Tatton N.A. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Transm. Suppl. 48:1996;45-59.
43. Tseng W.P., Lin-Shiau S.Y. Long-term lithium treatment prevents neurotoxic effects of beta- bungarotoxin in primary cultured neurons. J. Neurosci. Res. 69:2002;633-641.
44. Varney M.A., Godfrey P.P., Drummond A.H., Watson S.P. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells. Mol. Pharmacol. 42:1992;671-678.
45. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4- phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA. 98:2001;2837-2842.
46. Weinreb O., Mandel S., Youdim M.B.H. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. 17:2003;935-937.
47. Xu J., Culman J., Blume A., Brecht S., Gohlke P. Chronic treatment with a low dose of lithium protects the brain against schemic injury by reducing apoptotic death. Stroke. 3:2003;3.
48. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.C., Penney J.B. Jr., Hyman B.T., Beal M.F. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18:1998;8145-8152.
49. Youdim M.B.H. Rasagiline; an anti-Parkinson drug with neuroprotective activity. Expert Rev. Neurother. 3:(6):2003;737-749.
50. Youdim, M.B.H., 2003b. Submitted for publication.
51. Youdim, M.B.H., 2004. In preparation.
52. Youdim M.B.H., Tipton K.F. Rat striatal monoamine oxidases inhibition by I-deprenyl and rasagiline: its relationship to 2-phenylethylaminenduced stereotypy and Parkinson's disease. Parkinsonism Relat. Disord. 8:2002;247-253.
53. Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-propargyl-1R(+)- aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132:2001;500-506.
54. Youdim M.B.H., Wadia A., Tatton N.A., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939:2001;450-458.
55. Yuan P.X., Chen G., Huang L.D., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res. Mol. Brain Res. 58:1998;225-230.
56. Zhang A., Huang X., Luo P., Jiang X. Study on inhibition and prevention of tumor and antioxidative effects of lithium carbonate in tumor bearing mice. Wei Sheng Yan Jiu. 27:1998;77-80.